COMPARATIVE, WELL-CONTROLLED STUDY ON AMPICILLIN SUPPOSITORY (KS-R 1) WITH ORAL FORM OF AMPICILLIN ON URINARY TRACT INFECTIONS

Abstract

1. Subjects were in-patients with bacterial urinary tract infections, ranging in age 4 months to 11 years 4 months. As a rule, daily dose was either four 125 mg (in potency) suppositories or four 125 mg (in potency) oral form given at 6-hour intervals over a period of 5 days.
2. The number of children subjected to this study was 105. These children were divided into 2 groups (suppository 54; oral form 51) with matched pretreatment background factors.
3. Therapeutic effectiveness rates were 70.4% for the suppository and 66.7% for the oral form, and no significant difference was observed between the 2 groups. Rates of efficacy by severity, presence or absence of underlying and/or complication diseases, daily dose and causative microorganisms did not differ significantly between the 2 groups.
4. There was no significant difference in time-courses of improvement of clinical signs and symptoms between the 2 groups.
5. Eradication rates for causative microorganisms were 65.9% for the suppository and 62.5% for the oral form.
Most frequently isolated causative microorganisms were Escherichia coli and Proteus mirabilis.
6. No significant differences were recognized in the therapeutic effect and usefulness evaluated by physicians in charge.
7. The frequency of side effects did not differ significantly between the suppository group (6 with diarrhea and 1 with anal pain: 12.1%) and the oral form group (5 with diarrhea, 1 with displeasure and 1 with vomiting: 12.7%).
Abnormal laboratory findings appeared in 6 cases (2 with eosinophilia, 2 with increased GOT and 2 with increased GPT) in the suppository group and 7 cases (2 with eosinophilia, 2 with thrombocytosis, 2 with increased GOT and 1 with increased GPT) in the oral form group.